Oric Pharmaceuticals (ORIC) Research & Development (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Research & Development came in at $31.4 million in Q1 2026, up 27.59% YoY from $24.6 million in Q1 2025, and up 21.58% on a QoQ basis from $25.9 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Research & Development (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Research & Development data on file, last reported at $31.4 million in Q1 2026.
- Quarterly Research & Development rose 27.59% year-over-year to $31.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (changed 0.12% YoY) and the FY2025 annual result came in at $109.8 million, down 3.73% from the prior year.
- Research & Development climbed to $31.4 million in Q1 2026, from $25.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $32.0 million in Q4 2024 to a low of $13.8 million in Q2 2022.
- A 5-year average of $23.7 million and a median of $24.5 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development surged 54.04% — and 2025, when it retreated 19.12%.
- Tracing ORIC's Research & Development over 5 years: stood at $16.3 million in 2022, then jumped by 50.24% to $24.5 million in 2023, then soared by 30.59% to $32.0 million in 2024, then dropped by 19.12% to $25.9 million in 2025, then climbed by 21.58% to $31.4 million in 2026.
- The last three Research & Development figures came in at $31.4 million (Q1 2026), $25.9 million (Q4 2025), and $28.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 36.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.30 Mn |
| Mar 31, 2026 | 31.44 Mn |
| Dec 31, 2025 | 25.86 Mn |
| Sep 30, 2025 | 28.77 Mn |
| Jun 30, 2025 | 30.55 Mn |
| Mar 31, 2025 | 24.64 Mn |
| Dec 31, 2024 | 31.97 Mn |
| Sep 30, 2024 | 31.20 Mn |
| Jun 30, 2024 | 28.94 Mn |
| Mar 31, 2024 | 21.96 Mn |
| Dec 31, 2023 | 24.48 Mn |
| Sep 30, 2023 | 22.39 Mn |
| Jun 30, 2023 | 18.79 Mn |
| Mar 31, 2023 | 19.52 Mn |
| Dec 31, 2022 | 16.30 Mn |
| Sep 30, 2022 | 14.72 Mn |
| Jun 30, 2022 | 13.83 Mn |
| Mar 31, 2022 | 16.83 Mn |
| Dec 31, 2021 | 16.75 Mn |
| Sep 30, 2021 | 12.90 Mn |